Abivax (ABVX) Current Deferred Revenue (2023)

Abivax (ABVX) recorded quarterly Current Deferred Revenue of $55948.9 in Q4 2023.

Abivax (ABVX) Current Deferred Revenue (2023) Analysis & Trends

Abivax's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $55948.9 for Q4 2023.

In Q4 2023, Current Deferred Revenue changed N/A year-over-year to $55948.9; the TTM figure through Dec 2023 stood at $55948.9 (changed N/A YoY), while the FY2023 annual figure was $55948.9, changed N/A from the prior year.
Current Deferred Revenue was $55948.9 for Q4 2023 at Abivax.
In the past five years, Current Deferred Revenue ranged from a high of $55948.9 in Q4 2023 to a low of $55948.9 in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Regeneron Pharmaceuticals	66.09 Bn	57.33 Bn	3.31 Bn

Historic Data

Download Data

Date	Value
Dec 31, 2023	55,948.88